Atlas Pharmaceuticals, LLC, Phoenix, AZ

Is Atlas Pharmaceuticals, LLC registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels its entry 503B.

Does Atlas Pharmaceuticals, LLC hold a Arizona pharmacy license?

State board of pharmacy records for Arizona are not checked: the board’s website, which hosts its license verification and board orders, answers automated requests with a bot challenge, and this index does not work around blocks. The Delaware Division of Professional Regulation also lists nonresident license AD-0000069 for Atlas Pharmaceuticals, PHOENIX, AZ, status Closed, as of Nov 10, 2026.

Has Atlas Pharmaceuticals, LLC had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 FMD-145 letter (May 3, 2022) for Atlas Pharmaceuticals, LLC. State board of pharmacy records for Arizona are not checked: the board’s website, which hosts its license verification and board orders, answers automated requests with a bot challenge, and this index does not work around blocks.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Atlas Pharmaceuticals, LLC
Location
Phoenix, AZ
Type as FDA labels it
503B
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
2
Warning letters on FDA’s actions page
0
Latest action on that page
May 3, 2022
FDA Data Dashboard inspections
4 inspections: 1 OAI, 2 VAI, 1 NAI; 2 published Form 483s
Form 483 text on this page
2 Form 483s, 14 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Atlas Pharmaceuticals, LLC, a 503B facility, with 3 dated actions.

Document
May 3, 2022FMD-145 letterFMD-145 Letter Issued 05/03/2022Not linked by FDA
Jun 11, 2021Form 483483 Issued 06/11/2021FDA copy (archived)
May 21, 2021Form 483483 Issued 05/21/2021Not linked by FDA

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Atlas Pharmaceuticals, LLC, Phoenix, AZ (FEI number 3013030904), matched to this page by exact name, city and state. It lists 4 inspections: 1 OAI, 2 VAI, 1 NAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
May 21, 2021Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30130309041142452
Sep 26, 2017Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30130309041026743
May 30, 2014Voluntary Action Indicated (VAI)Monitoring of Marketed Animal Drugs, Feed, and Devices (Veterinary)3013030904881606
Dec 21, 2011No Action Indicated (NAI)Monitoring of Marketed Animal Drugs, Feed, and Devices (Veterinary)3013030904759718

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 14 numbered observations in all, across 2 inspections ending Sep 26, 2017 to May 21, 2021. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection May 3, 2021 to May 21, 2021: 3 observations

Firm on the cover
Atlas Pharmaceuticals, LLC, 711 E Carefree Hwy Ste 107, Phoenix, AZ 85085-0103
FEI number
3013030904
Establishment type on the cover
outsourcing facility
FDA district office on the cover
19701 Fairchild I rvine, CA 92612-2445
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

Specifically, personnel and environmental monitoring specifications for the ISO 5 areas appear inadequate and the approved environmental monitoring procedure does not always require an investigation when viable microorganisms are recovered. The action limit for gloved fingertips of aseptic processing personnel during routine sampling is <Redacted B4> CFU. A gloved fingertip sample exhibited growth <Redacted B4> CFU, on 06/17/20 after production of buprenorphine, 0.15 mg/ ml injection, lot S-60357, released 07/13/20. This value was below the action limit, and there was no investigation of the potential impact to this lot.

Observation 2

Determinations of conformance to appropriate written specifications for acceptance are deficient for drug products.

Specifically, the visual inspection procedure and the training of personnel to perform visual inspection appear deficient.

A) One QA specialist identified <Redacted B4> vials <Redacted B4>% contained articulates during visual of dexmedetomidine HC, 1mg/mL injection, lot S-60399. This result exceeded the initial inspection action limit specification of less than <Redacted B4>%. The suspect units were <Redacted B4> QA specialist identified <Redacted B4> vials <Redacted B4>% contained particulates during the re-inspection approximately 15 days later. This was below the re-inspection action limit <Redacted B4> QA released this lot without a written investigation of the discrepancy between the <Redacted B4> inspections performed by qualified personnel.

AMENDMENT2

of the discrepancy between ther(bl (4I inspections performed by qualified personnel.

B) The reinspection process defined in the approved visual inspection procedure, Q-23 Visual Inspection of Sterile Injectable Finished Product, requires QA personnel to <Redacted B4>. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process.

Specifically,

A) The firm did not conduct media fills prior to resuming sterile production after two extended shutdowns for repairs.

a.

There was no media fill prior to reopening the cleanroom to produce sterile drugs on <Redacted B4>/20. The facility was shut down approximatey <Redacted B4> to repair water damage caused by <Redacted B4> water system leak on <Redacted B4> /20. There was inadequate assurance production processes were suitable to produce <Redacted B4> of sterile human drugs and approximately <Redacted B4> of sterile veterinary drugs prior to completing media fills on 02/03/ 21.

b. There was no media fill prior to reopening the cleanroom to produce sterile drugs or <Redacted B4> /20. The facility was shut down approximately <Redacted B4> to repair drywall and repaint the sterile production suite. ...

Read the full 483 (PDF on fda.gov)

Inspection Aug 15, 2017 to Sep 26, 2017: 11 observations

Firm on the cover
Atlas Pharmaceuticals, LLC, 711 E. Carefree Highway Suite 107, Phoenix, AZ 85085-0101
FEI number
3013030904
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
District, Address, and Phone Number: 19701 Fairchild Irvine, CA 92612-2445
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

Specifically,

A. Your firm failed to perform and document an investigation into a media fill failure and also determine the root cause of the contaminant. Your firm's first media fill, lot number <Redacted B4, 6> performed on 06/06/2017 by your Operator, Pharmacy Technician <Redacted B6>, failed. One (1) vial was observed to have growth on 06/12/2017. Your firm identified the contaminant as Bacillus licheniformis. Your written procedure titled, "S-09 Media Fill Trial" states <Redacted B4> Furthermore, you produced Ascorbic Acid, lot number S-60008 (50 ml Amber Vial) on 6/22/2017. You distributed product to a customer on 07/07/2017 and 08/30/2017. This initial media fill failure was repeated multiple times, with the deficiencies listed below.

•••1

I . When your firm had Operator. Pharmacy Technician <Redacted B6> repeat his media fill as lot number <Redacted B4> 06/23/2017, he did not perform a repeat of a full batch size, which consists of <Redacted B4>. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

A. There are deficiencies in environmental monitoring, specifically, viable air, surface, and personnel monitoring records. Examples include, but are not limited to, the items listed below.

I. Your "Cleanroom Media Samples" log that is used by your firm to document environmental monitoring results for viable air samples and surface samples does not indicate pass/fail specifications.

2. There are no results for viable air and surface monitoring for the date of production of Ascorbic Acid 500mg/mL Injection in 50mL, lot S-60008 on 06/22/2017.

3. There are multiple instances of poor documentation practices, such as late entries and not indicating the number of days incubated <Redacted B4> observed on the "Cleanroom Media Samples" log and late entries on the "Routine Fingertip Sampling Form".

4. The <Redacted B4> fingertip and <Redacted B4> body sampling forms appear to have missing dates for both sterile production Operators, specifically on 06/06/2017 and on 06/22/20 I 7, when media fill trials and sterile drug production occurred.

5. 5. ...

Read the full 483 (PDF on fda.gov)

Observation 3

There is a lack of written procedures describing in sufficient detail the methods, equipment and materials to be used for sanitation.

Specifically,

A. Your firm's written procedure titled, "S-10 Sterile Lab Cleaning Version I" and the firm's "Cleaning Log(s)" for the Non-Sterile Compounding (production) Room; ISO 8 Areas; and ISO 7 Areas are deficient. Deficiencies include, but are not limited to the items listed below.

I. Specific details regarding your cleaning method are not included in procedure S-10. Examples include, but are not limited to: how a <Redacted B4> is performed; how cleaning agents are <Redacted B4> ; the specific

contact time for each cleaning agent; and how large of an area can be cleaned before <Redacted B4> the <Redacted B4> and in which order the cleaning agents are to be used.

2. The Cleaning Logs do not specify the following: the room(s) and/or locations in the ISO 7 areas that were cleaned; the lot number(s) and expiration date(s) of cleaning agents that were used; and <Redacted B4> cleaning as required per procedure S-10 was not always performed and/or documented.

B. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Employees engaged in the manufacture, processing, packing and holding of a drug product Jack the education, training and experience required to perform their assigned functions.

Specifically, there are deficiencies in your firm's employee training. Examples include, but are not limited to the items listed below.

B. Your firm stated that Operators were trained by an external comany to conduct <Redacted B4> testing. However, as late as 08/25/2017, Operators who conduct <Redacted B4> testing did not have documentation to show that this training was completed.

Observation 5

Determinations of conformance to appropriate written specifications for acceptance are deficient for drug products.

Specifically, the alert and action levels specified in your written procedure titled, "Q-17 Testing and Release Criteria for Sterile Products" were established per the recommendation of your consultant and not according to an additional statistical basis or scientific rationale. Procedure Q-17 states that <Redacted B4> product procedure Q-17 requires your firm to perform <Redacted B4>

Observation 6

Laboratory controls do not include the establishment of scientifically sound and appropriate specifications, standards and test procedures designed to assure that components, in-process materials and drug products confonn to appropriate standards of identity, strength, quality and purity.

Specifically,

Your firm does not have an established written procedure to define solution expiration dating. In the ISO 8 Mixing Room on 09/19/2017, I examined <Redacted B4> an <Redacted B4> solutions which are used to adjust the pH of drug product bulk solutions. Each solution had different lengths assigned for expiration dating. There were examples o <Redacted B4> expiration dates assigned to different lots of these solutions that are prepared at the firm. Examples include at were not limited to the solutions listed below.

Observation 7

Equipment and utensils are not cleaned, maintained and sanitized at appropriate intervals to prevent malfunctions and contamination that would alter the safety, identity, strength, quality or purity of the drug product.

Specifically,

A. Your firm's written procedure titled, <Redacted B4> Use, Cleaning and Maintenance" requires that maintenance and cleaning of the <Redacted B4> is to be performed <Redacted B4> and <Redacted B4>. Your firm has no documentation to show that such maintenance and cleaning activities are performed per procedure E-01 .

B. Your firm has a pH meter located in the ISO 8 Mixing Room. This pH meter is documented as calibrated <Redacted B4> however, your calibration log does not specify which pH reference standards are used or include calibration reading results.

Observation 8

The batch production and control records are deficient in that they do not include documentation of the accomplishment of each significant step in manufacturing, processing, packing and holding.

Specifically, there are deficiencies in the "Master Formulation Record" (batch record) for the Ascorbic Acid 500mg/mL Injection in 50mL drug product, lot number S-60008 dated 06/22/2017 and for the Media Fill Challenge (media fill batch record) dated 06/06, 12, 15, and 23/2017. Examples of batch record deficiencies included, but were not limited to the items listed below.

• Missing equipment lot numbers; • Missing lot numbers and missing expiration or use by date for sterilized items, such as <Redacted B4> containers and closures;

• No documentation by Operator(s) to show that each step was completed; and • No documentation of the product <Redacted B4> test

Observation 9

Drug products are not stored under appropriate conditions of temperature so that their identity, strength, quality, and purity are not affected.

Specifically, on 8/15/2017, I observed vials of Ascorbic Acid lot number S-60008 that to restored as "Released" (by Quality) product in your firm's Active Stock and Shipping Area. The product label on Ascorbic Acid lot# S-60008 instructs users to store the product at 2°C to 8°C; however, these vials were being stored at ambient temperature.

Observation 10

There is no written testing program designed to assess the stability characteristics of drug products.

Specifically, your firm has sent "stability samples" to your third party laboratory to test container/closure, identity, and potency. However, no protocols or documents exist to indicate parameters, including, but not limited to: dates when samples were placed on stability; dates when samples were pulled for stability; or stability sample storage conditions.

Observation 11

The labels ofyour outsourcing facility's drug products are deficient.

Specifically,

The labels of your outsourcing facility's drug products do not include information required by section 503B(a)(10)(A}. Specifically,

• The statement, "Not for resale," is not on your drug product labels . Labels for the following drug product

do not contain this statement:

• Ascorbic Acid Injection 500 mg/mL, 50 mL vial

State board of pharmacy records

State board of pharmacy records for Arizona are not checked: the board’s website, which hosts its license verification and board orders, answers automated requests with a bot challenge, and this index does not work around blocks.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).

LicenseType as the board gives itName on the board recordLocationStatus
AD-0000069Outsourcing Facility-DistributorAtlas PharmaceuticalsPHOENIX, AZClosed

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.